The U.S. began vaccinating the population against the coronavirus earlier this month, but mass adoption is not a guarantee. Roughly four in ten Americans say they would “definitely” or “probably” not get a vaccine, according to a recent survey by…
CNBC’s “Closing Bell” team reports on President-elect Joe Biden receiving his first dose of Pfizer’s coronavirus vaccine. For access to live and exclusive video from CNBC subscribe to CNBC PRO: President-elect Joe Biden received a Covid-19 vaccine on live television…
#COVID19 #coronavirus #vaccines During this lecture we will be discussing COVID-19 vaccines including Moderna, Pfizer/BioNTech, and Astrazeneca/Oxford. We are NOT sponsored and/or endorsed by Moderna, Pfizer/BioNTech, or Astrazeneca. We are presenting on RESEARCH and in no way is any of…
Ronny Gal, Bernstein senior analyst, joins ‘Closing Bell’ to discuss the timeline for when the U.S. could reach herd immunity on Covid-19 once there is a readily available vaccine. He also talks about the vaccine’s impact on markets. For access…
The U.S. Food and Drug Administration on Thursday approved the emergency use of Eli Lilly’s arthritis drug baricitinib, in combination with Gilead Sciences’ remdesivir, to treat Covid-19 patients. On Thursday, a WHO panel advised doctors against using remdesivir as a…
Moderna’s vaccine, created with the National Institutes of Health, is being studied in 30,000 volunteers who received either the real vaccination or a dummy shot For the second time this month, there’s promising news from a COVID-19 vaccine candidate: Moderna…
